Abstract: The present invention relates to a substance interacting with C terminal fragment of the STIM1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers. The present invention further relates to a pharmaceutical composition comprising at least one substance interacting with C terminal fragment of the STIM1 fraction localized to the plasma membrane of cells, and at least one pharmaceutically acceptable excipient. The invention also refers to the use of isolated C terminal fragment of the STIM1 fraction localized to the plasma membrane of cells in a method for screening candidate molecules for treating cancers, especially pancreatic, colon, breast, Burkitt lymphoma or chronic Lymphocytic Leukaemia. The present invention also relates to a process for predicting the progression and/or monitoring the progression of a cancer, comprising the in vitro detection of the expression of STIM1 in a sample of the tumour of the subject.

Abstract: The present invention relates to a compound that specifically binds to the region between amino acid residues 58 and 201, preferably 97 and 127 of human STIM1 (SEQ ID NO: 1). The present invention also relates to a composition comprising a therapeutically effective amount of the compound, a host cell that produces an isolated antibody, an isolated nucleic acid sequence encoding the isolated antibody and an expression vector comprising the nucleic acid. The present invention additionally relates to a method of producing the isolated antibody, to the isolated antibody for its use as a drug, especially for its use in treating a condition or a disorder in which the STIM1 protein localized to the plasma membrane of the cells is overexpressed, and to an isolated protein fragment consisting of the region between amino acid residues 97 and 127 for developing modulators of STIM1 (SEQ ID NO: 1).

Abstract: The present invention relates to a compound that specifically binds to the region between amino acid residues 58 and 201 of human STIM1 (SEQ ID NO: 1). The present invention also relates to a composition comprising a therapeutically effective amount of the compound, a host cell that produces an isolated antibody, an isolated nucleic acid sequence encoding the isolated antibody and an expression vector comprising the nucleic acid. The present invention additionally relates to a method of producing the isolated antibody, to the isolated antibody for its use as a drug, especially for its use in treating a condition or a disorder in which the STIM1 protein localized to the plasma membrane of the cells is overexpressed, and to an isolated protein fragment consisting of the region between amino acid residues 58 and 201 for developing modulators of the STIM1 amino acid sequence SEQ ID NO: 1.